{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:59:20Z","timestamp":1792299560318,"version":"4.4.0"},"reference-count":40,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.<\/jats:p>","DOI":"10.1136\/pn-2024-004228","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T23:55:21Z","timestamp":1731369321000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance"],"prefix":"10.1136","volume":"25","author":[{"given":"Waqar","family":"Rashid","sequence":"first","affiliation":[{"name":"St George's University Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London Queen Square Institute of Neurology, London, UK"},{"name":"NIHR UCLH BRC, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan M","family":"Leary","sequence":"additional","affiliation":[{"name":"UCLH NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-3615","authenticated-orcid":false,"given":"Tarunya","family":"Arun","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Doshi","sequence":"additional","affiliation":[{"name":"NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London Queen Square Institute of Neurology, London, UK"},{"name":"Darent Valley Hospital, Dartford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Evangelou","sequence":"additional","affiliation":[{"name":"Mental Health and Clinical Neurosciences Academic Unit, University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L","family":"Ford","sequence":"additional","affiliation":[{"name":"Leeds Centre for Neurosciences, Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"University of Leeds Faculty of Medicine and Health, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hobart","sequence":"additional","affiliation":[{"name":"Peninsula Medical School, University of Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-454X","authenticated-orcid":false,"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"},{"name":"Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-1218","authenticated-orcid":false,"given":"Paolo Antonio","family":"Muraro","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Murray","sequence":"additional","affiliation":[{"name":"Anne Rowling Regenerative Neurology Clinic, University of Edinburgh Western General Hospital, Edinburgh, UK"},{"name":"Department of Neurology, Forth Valley Royal Hospital, Larbert, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal London Hospital for Integrated Medicine, London, UK"},{"name":"Centre for Preventative Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"2025090411022857000_25.1.18.1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001139"},{"key":"2025090411022857000_25.1.18.2","unstructured":"Disease modifying treatments (dmts) in relapsing remitting multiple sclerosis (rrms). n.d. Available: https:\/\/rightdecisions.scot.nhs.uk\/ggc-clinical-guideline-platform\/central-nervous-system\/multiple-sclerosis\/disease-modifying-treatments-dmts-in-relapsing-remitting-multiple-sclerosis-rrms-113"},{"key":"2025090411022857000_25.1.18.3","unstructured":"NHS England . Treatment algorithm for multiple sclerosis disease-modifying therapies. 2018. Available: https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2019\/03\/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf"},{"key":"2025090411022857000_25.1.18.4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025090411022857000_25.1.18.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20588"},{"key":"2025090411022857000_25.1.18.6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025090411022857000_25.1.18.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"2025090411022857000_25.1.18.8","unstructured":"CTG labs - ncbi. n.d. Available: https:\/\/clinicaltrials.gov\/study\/NCT03535298"},{"key":"2025090411022857000_25.1.18.9","unstructured":"CTG labs - NCBIi. n.d. Available: https:\/\/clinicaltrials.gov\/study\/NCT03500328"},{"key":"2025090411022857000_25.1.18.10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/13524585231151951","article-title":"Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis","volume":"29","author":"Daruwalla","year":"2023","journal-title":"Mult Scler"},{"key":"2025090411022857000_25.1.18.11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/WCO.0000000000000456","article-title":"Imaging markers of multiple sclerosis prognosis","volume":"30","author":"Louapre","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"2025090411022857000_25.1.18.12","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/brain\/awz156","article-title":"Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis","volume":"142","author":"Brownlee","year":"2019","journal-title":"Brain (Bacau)"},{"key":"2025090411022857000_25.1.18.13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.26555","article-title":"Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome","volume":"93","author":"Okuda","year":"2023","journal-title":"Ann Neurol"},{"key":"2025090411022857000_25.1.18.14","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","article-title":"Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial","volume":"80","author":"Lebrun-Fr\u00e9nay","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025090411022857000_25.1.18.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"2025090411022857000_25.1.18.16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol Ther"},{"key":"2025090411022857000_25.1.18.17","doi-asserted-by":"crossref","unstructured":"Rotstein D , et al . Association of NEDA-4 with no long-term disability progression in multiple sclerosis and comparison with NEDA-3. Neurol Neuroimmunol Neuroinflamm 2022;9.","DOI":"10.1212\/NXI.0000000000200032"},{"key":"2025090411022857000_25.1.18.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322348"},{"key":"2025090411022857000_25.1.18.19","article-title":"Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity","volume":"103","author":"Bsteh","year":"2024","journal-title":"Neurol (ECronicon)"},{"key":"2025090411022857000_25.1.18.20","doi-asserted-by":"crossref","unstructured":"Hillert J , Magyari M , Soelberg S\u00f8rensen P , et al . Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Front Neurol 2021;12. doi:10.3389\/fneur.2021.647811","DOI":"10.3389\/fneur.2021.647811"},{"key":"2025090411022857000_25.1.18.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0183-3"},{"key":"2025090411022857000_25.1.18.22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis","volume":"12","author":"Vollmer","year":"2021","journal-title":"Front Neurol"},{"key":"2025090411022857000_25.1.18.23","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00154-0"},{"key":"2025090411022857000_25.1.18.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44750","article-title":"Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy","volume":"5","author":"Hellwig","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025090411022857000_25.1.18.25","first-page":"e2989","article-title":"Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis","volume":"96","author":"Yeh","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025090411022857000_25.1.18.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00426-4"},{"key":"2025090411022857000_25.1.18.27","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000959","article-title":"Clinical and radiologic disease activity in pregnancy and postpartum in MS","volume":"8","author":"Anderson","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090411022857000_25.1.18.28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jns.2018.12.028","article-title":"Effect of pregnancy loss on MS disease activity","volume":"397","author":"Kaplan","year":"2019","journal-title":"J Neurol Sci"},{"key":"2025090411022857000_25.1.18.29","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513507816"},{"key":"2025090411022857000_25.1.18.30","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200106","article-title":"Inflammatory Activity After Diverse Fertility Treatments: A Multicenter Analysis in the Modern Multiple Sclerosis Treatment Era","volume":"10","author":"Graham","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090411022857000_25.1.18.31","first-page":"e1916","article-title":"Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis","volume":"99","author":"Mainguy","year":"2022","journal-title":"Neurology (ECronicon)"},{"key":"2025090411022857000_25.1.18.32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jamaneurol.2019.4173","article-title":"Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses: A Systematic Review and Meta-analysis","volume":"77","author":"Krysko","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025090411022857000_25.1.18.33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: \u201cAssociation of British Neurologists\u201d guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract Neurol"},{"key":"2025090411022857000_25.1.18.34","unstructured":"Overview | multiple sclerosis in adults: management | guidance | NICE Guideline 2022."},{"key":"2025090411022857000_25.1.18.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0684-0"},{"key":"2025090411022857000_25.1.18.36","first-page":"e890","article-title":"Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series","volume":"97","author":"Nicholas","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025090411022857000_25.1.18.37","unstructured":"CTG labs - NCBI. n.d. Available: https:\/\/clinicaltrials.gov\/study\/NCT04047628"},{"key":"2025090411022857000_25.1.18.38","unstructured":"Prizes N , StarMS trial . The university of sheffield. 2023. Available: https:\/\/www.sheffield.ac.uk\/ctru\/current-trials\/starms"},{"key":"2025090411022857000_25.1.18.39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025090411022857000_25.1.18.40","doi-asserted-by":"crossref","unstructured":"Solomon AJ , Marrie RA , Viswanathan S , et al . Global Barriers to the Diagnosis of Multiple Sclerosis. Neurology (ECronicon) 2023;101. doi:10.1212\/WNL.0000000000207481","DOI":"10.1212\/WNL.0000000000207481"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2024-004228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:12:57Z","timestamp":1757009577000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2024-004228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,16]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/pn-2024-004228"],"URL":"https:\/\/doi.org\/10.1136\/pn-2024-004228","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}